why choose us

First received: May 12, 2023

Clinical Trial: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Endometrial Serous Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Brief Summary: This phase II trial tests how well niraparib and dostarlimab work in treating patients with uterine serous carcinoma that has come back (after a period of improvement) (recurrent) and remains despite treatment (persistent).Niraparib belongs to a class of drugs called PARP inhibitors that prevent cancer cells from growing.Dostarlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.Dostarlimab belongs to a class of drugs called PD-1 inhibitors that uses the…

Read more